Shattuck Labs reported Phase 1 data for SL-325 showing a potentially best-in-mechanism immunogenicity profile with only 3.7% antidrug antibodies and complete TL1A blockade lasting over 3 months. The company plans to initiate Phase 2b trials in Crohn's disease in Q3 2026, advancing its pipeline of DR3-targeting therapeutics.